Posted innews Pediatrics
Atosiban Did Not Improve Neonatal Outcomes for Threatened Preterm Birth at 30–34 Weeks: Results from the Multicentre APOSTEL 8 Trial
In the APOSTEL 8 randomized trial, intravenous atosiban did not reduce a composite of perinatal mortality and severe neonatal morbidity versus placebo for threatened preterm birth at 30+0–33+6 weeks.